Real life issues & answers: The Lipid disorder patient (incl. FH)

Speakers: ,

This sponsored workshop has been organised and funded by BHF

This presentation will cover:

The rationale behind current initiatives to identify patients and families with Familial Hypercholesterolaemia (FH); the value of genetic testing for informing prognosis, facilitating family screening  and improving compliance with treatment; primary care case finding strategies, and pathways for referral for genetic testing under new commissioning arrangements.

The current evidence base for lipid lowering, including use of Ezetimibe, indications for use of PCSK9 inhibitors, treatment targets, options for patients with statin intolerance, the implications of the ‘legacy effect’ of statin treatment, and lipid lowering therapy in the elderly.

« Back to Interactive Programme